Phase 3 Completed N=30 Randomized Double-blind Treatment

Atorvastatin for HAART Suboptimal Responders

Acquired Immune Deficiency Syndrome Virus

Source: ClinicalTrials.gov NCT01766076 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2015

Primary outcomePrimary: Percentage Change in Immune Activation Levels After 12 Weeks of Atorvastatin 80mg Daily — 60; 21 percentage change in activated T-cells — p=<0.05

Summary

We hypothesise that atorvastatin changes immune activation among HAART-treated adults with suboptimal cluster cell differentiation 4 (CD4) recovery by 25%

Outcome Measures

Outcome	Result	p-value
PRIMARY Percentage Change in Immune Activation Levels After 12 Weeks of Atorvastatin 80mg Daily	60; 21	<0.05 sig

Eligibility Criteria

List of inclusion Criteria: HIV-infected adults on antiretroviral therapy for at least 6 years with sustained viral suppression (viral load<400 copies), and CD4 increase below 300 cells (difference between current and baseline CD4 count). List of exclusion Criteria: History of an opportunistic infection within the previous six months, Pregnancy, History of myositis, History of ingestion of lipid-lowering agents at the baseline visit, Use of therapeutic agents known to have substantial drug-drug interactions with statins, and individuals on PI-containing HAART

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01766076). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.